Quick Answer
MoonLake Immunotherapeutics reported Stockholders Equity of $304.48 million for the year ending 2025.
- MoonLake Immunotherapeutics showed a decrease of -31.9% in Stockholders Equity from 2024 to 2025.
- This data is from MoonLake Immunotherapeutics's annual report (Form 10-K), filed with the SEC on February 25, 2026.
- XBRL data for this metric is available from 2020 to 2025 (6 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q3 2020: $20.0 thousand | Q1 2021: -$2.59 million | Q2 2021: $5.00 million | Q3 2021: -$4.84 million | Q1 2022: $24.40 million | Q2 2022: $63.51 million | Q3 2022: $55.29 million | Q1 2023: $42.00 million | Q2 2023: $489.80 million | Q3 2023: $424.93 million | Q1 2024: $542.55 million | Q2 2024: $520.66 million | Q3 2024: $488.20 million | Q1 2025: $407.52 million | Q2 2025: $353.73 million | Q3 2025: $288.91 million.
- Over the full 6 years of available data (2020 to 2025), MoonLake Immunotherapeutics's Stockholders Equity has grown by 12,200.4%.
- Historical annual values: Fiscal year 2025: $304.48 million | Fiscal year 2024: $446.83 million | Fiscal year 2023: $495.68 million | Fiscal year 2022: $48.90 million | Fiscal year 2021: -$11.65 million | Fiscal year 2020: -$2.52 million.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: